Repurposed AT9283 triggers anti-tumoral effects by targeting MKK3 oncogenic functions in Colorectal Cancer
Overall, we demonstrated that the anti-tumoral effects triggered by AT9283 treatment recapitulated the MKK3 depletion effects in all tested CRC models in vitro and in vivo, suggesting that AT9283 is a repurposed drug. According to its good tolerance when tested with primary colonocytes (CCD-18CO), AT9283 is a promising drug for the development of novel therapeutic strategies to target MKK3 oncogenic functions in late-stage and metastatic CRC patients.
Authors
- Emanuela Dell’Aquila (ORCID: https://orcid.org/0000-0002-7258-1364)
- Federica Ganci (ORCID: https://orcid.org/0000-0002-8010-2183)
- Valentina Piastra (ORCID: https://orcid.org/0000-0002-9427-2239)
- Roberta Bernardini (ORCID: https://orcid.org/0000-0002-1675-0645)
- Matteo Allegretti (ORCID: https://orcid.org/0000-0003-3398-8775)
- Angelina Pranteda (ORCID: https://orcid.org/0000-0001-7351-6348)
- Armando Bartolazzi (ORCID: https://orcid.org/0000-0001-7820-5127)
- Giovanni Blandino (ORCID: https://orcid.org/0000-0002-6970-2241)
- Livio Trusolino (ORCID: https://orcid.org/0000-0002-6379-3365)
- G. Ferretti (ORCID: https://orcid.org/0000-0002-2271-6427)
- Andrea Sacconi (ORCID: https://orcid.org/0000-0002-8276-0438)
- Barbara Lupo (ORCID: https://orcid.org/0000-0002-4383-6882)
- Gianluca Bossi (ORCID: https://orcid.org/0000-0002-2947-1063)
- Edoardo Pescarmona (ORCID: https://orcid.org/0000-0002-0443-9331)
- Martina Serra (ORCID: https://orcid.org/0000-0002-3932-9861)
Institutions
- University of Rome Tor Vergata (IT)
- Roma Tre University (IT)
- CTO Andrea Alesini (IT)
- National Cancer Institute (MY)
- Candiolo Cancer Institute (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Turin (IT)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1186/s13046-024-03150-4
- Citations
- 6
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Ministero della Salute
- Associazione Italiana per la Ricerca sul Cancro